Modi Ventures, a newly launched venture partnership investing in fund managers and founders building companies shaping the future of humanity, today announ...
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make ...
Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A liv...
Lenexa, Kansas, USA facility becomes company’s largest dry powder cell culture media facility and Center of Excellence in North America Boos...
“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silenc...
Co-led by William Abecassis, Braven’s Managing Partner, and Dr. Sean Khozin, Senior Life Sciences & Healthcare Partner, the Unit supports the fir...
Under CEO Alan Hirzel’s leadership, Abcam has transformed as a business, created significant value for all stakeholders, and outperformed the m...
Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...
Gavi, the Vaccine Alliance, and the Eleanor Crook Foundation (ECF) announced at the Global Vaccine Impact Conference a US$2 million joint investment in the...
The record date will be 5 p.m. Burlington, North Carolina time on Tuesday, June 20, 2023, and The distribution date will be 11:59 p.m. Burlington, North...
$7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group. Existing investors Cambridge Enterpris...
DF-006 is a first-in-class, orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver, leading to a ro...
Agilent Technologies Inc. (NYSE: A) announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on July 26, 2023, ...
$3,000,000,000 aggregate principal amount of 4.650% Notes due 2025 $3,000,000,000 aggregate principal amount of 4.450% Notes due 2026 $4,000,000,000 aggr...
© 2024 Biopharma Boardroom. All Rights Reserved.
